Fundraising Fox

AZTherapies

Boston, US · Founded 2011 · Delaware corporation

Biotech

Founders & leadership

AZTherapies was founded in 2011 by David R Elmaleh.

DR
David R ElmalehFounder

Board

KG
Keith GreenfieldBoard director
PC
Peter ContiBoard director
RT
Ronald TompkinsBoard director
JP
John PorterBoard director

Reported raises · per SEC filings

Form D private placements

$85.8M disclosed across 8 rounds · 2014–2020

▶$14.8MraisedSep 2020 · 59 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter ContiDirector
  • George BehrakisDirector
  • Thierry PorteDirector
  • Brian BartlettExecutive Officer
  • Noah GottdienerDirector
  • Karen ReevesExecutive Officer
  • David TaftDirector
  • Gillian SandlerDirector
  • David ElmalehExecutive Officer, Director
  • Keith GreenfieldDirector
Offering amount
$35M
Amount sold
$14.8M
First sale
Aug 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$19MraisedJul 2019 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David R.. ElmalehExecutive Officer, Director
  • Robert S. WarrenExecutive Officer
  • Keith GreenfieldDirector
  • David TaftDirector
  • Ronald TompkinsDirector
  • Brian BartlettExecutive Officer
  • George T. BehrakisDirector
  • Gillian SandlerDirector
  • Karen ReevesExecutive Officer
  • Jay MohrExecutive Officer
  • Peter ContiDirector
Offering amount
$37.5M
Amount sold
$19M
First sale
Jun 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.6MraisedMay 2019 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John PorterDirector
  • Karen ReevesExecutive Officer
  • David R. ElmalehExecutive Officer, Director
  • Gillian SandlerDirector
  • Peter ContiDirector
  • Keith GreenfieldExecutive Officer, Director
  • Robert S. WarrenExecutive Officer
  • David TaftDirector
  • Ronald TompkinsDirector
Offering amount
$7.5M
Amount sold
$5.6M
First sale
May 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.1MraisedOct 2018 · 35 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ronald TompkinsDirector
  • Peter ContiDirector
  • Gillian SandlerDirector
  • Robert S. WarrenExecutive Officer
  • John PorterDirector
  • David R. ElmalehExecutive Officer, Director
  • Keith GreenfieldExecutive Officer, Director
  • Karen ReevesExecutive Officer
  • David TaftDirector
Offering amount
$25.5M
Amount sold
$16.1M
First sale
Jun 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.6MraisedDec 2017 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ronald TompkinsDirector
  • Peter ContiDirector
  • Robert S. WarrenExecutive Officer
  • John PorterDirector
  • Keith GreenfieldExecutive Officer, Director
  • David TaftDirector
  • David R. ElmalehExecutive Officer, Director
Offering amount
$6M
Amount sold
$1.6M
First sale
Dec 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.5MraisedNov 2017 · 43 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith GreenfieldExecutive Officer, Director
  • David R. ElmalehExecutive Officer, Director
  • David TaftDirector
  • Ronald TompkinsDirector
  • Robert S. WarrenExecutive Officer
  • Peter ContiDirector
  • John PorterDirector
Offering amount
$7.6M
Amount sold
$6.5M
First sale
Jun 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.1MraisedFeb 2017 · 41 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith GreenfieldExecutive Officer, Director
  • Ronald TompkinsDirector
  • Robert S. WarrenExecutive Officer
  • John PorterDirector
  • Peter ContiDirector
  • David R. ElmalehExecutive Officer, Director
  • David TaftDirector
Offering amount
$20M
Amount sold
$16.1M
First sale
Nov 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.1MraisedJan 2015 · 15 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith GreenfieldDirector
  • Peter ContiDirector
  • Ronald TompkinsDirector
  • David R ElmalehExecutive Officer, Director
  • John PorterDirector
Offering amount
$13M
Amount sold
$6.1M
Minimum investment
$25K
Proceeds to insiders
$150K
First sale
Dec 2014
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

AZTherapies Closes $33.6M Series C-1 Financing - FinSMEsfinsmes.com · Oct 2020AZTherapies Announces Closing of Series C-1 Financingaztherapies.com · Sep 2020AZTherapies Closes $26.3 Million Series C Preferred Equity FinancingProceeds to support ongoing Phase 3 Alzheimer’s clinical trial, expected to complete in 2020, and advancement of pipeline of candidates targeting neuroinflammation - BioSpacebiospace.com · Oct 2019AZTherapies - Tech Company Profile - Gaebler.com Venture Capital Databasegaebler.com

Frequently asked questions

Who founded AZTherapies?
AZTherapies was founded by David R Elmaleh in 2011.
How much funding has AZTherapies raised?
AZTherapies has disclosed $85.8M raised across 8 rounds.
Where is AZTherapies headquartered?
AZTherapies is headquartered in Boston, US.